This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This NMT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 125-153 amino acids from the C-terminal region of human NMT2.
NMT2
Reaktivität: Human
WB, IF (cc), IF (p)
Wirt: Kaninchen
Polyclonal
AbBy Fluor® 350
Applikationshinweise
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
N-myristoyltransferase (NMT) catalyzes the reaction of N-terminal myristoylation of many signaling proteins. It transfers myristic acid from myristoyl coenzyme A to the amino group of a protein's N-terminal glycine residue. Biochemical evidence indicates the presence of several distinct NMTs, varying in apparent molecular weight and /or subcellular distribution. The predicted 498-amino acid of human NMT2 protein shares 77 % and 96 % sequence identity with human NMT1 and mouse Nmt2 comprise two distinct families of N-myristoyltransferases.